Merck KGaA's Belén Garijo (AP Images)

Mer­ck KGaA snaps up Ger­man CD­MO in boost to mR­NA port­fo­lio — in­clud­ing for Covid-19

Once thought un­like­ly as a mech­a­nism of ac­tion in vac­cines, mR­NA-based shots have stormed out to a lead in the fight against Covid-19. But mR­NA’s po­ten­tial ef­fect isn’t lim­it­ed to just vac­cines, and now Ger­man drug­mak­er Mer­ck KGaA is look­ing to find out just how far it can take the tech­nol­o­gy.

The Darm­stadt, Ger­many based bio­phar­ma has ac­quired mR­NA CD­MO AmpTec in Ham­burg, say­ing it plans to strength­en its own ca­pac­i­ties to de­vel­op and man­u­fac­ture mR­NA for cus­tomers to use in “vac­cines, treat­ments and di­ag­nos­tics ap­plic­a­ble in Covid-19 and many oth­er dis­eases.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.